Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing, 100020, PR China.
Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing, 100020, PR China.
Asian J Surg. 2024 Jan;47(1):163-168. doi: 10.1016/j.asjsur.2023.06.065. Epub 2023 Jul 5.
Sarcomatoid renal cell carcinoma (sRCC) accounts for about 4%-5% of all kidney cancers. Previous studies showed that PD-1 and PD-L1 expression was higher in sRCC compared to non-sRCC. In the present study, we aimed to investigate PD-1/PD-L1 expression and its association with clinicopathological features in sRCC.
The study included 59 patients diagnosed with sRCC between January 2012 and January 2022. The expression of PD-1 and PD-L1 in sRCC was detected by immunohistochemical staining, and its correlation with clinicopathological parameters was analyzed by χ2 test and Fisher exact test. Kaplan-Meier curves and log-rank tests were used to describe the overall survival (OS). The prognostic significance of clinicopathological parameters on OS was assessed by Cox proportional hazards regression analysis.
Among the 59 cases, the positive expression of PD-1 and PD-L1 was 34 cases (57.6%) and 37 cases (62.7%), respectively. PD-1 expression was not significantly correlated with any parameters. However, PD-L1 expression was significantly correlated with tumor size and pathologic T stage. OS was shorter in the subgroup of patients with PD-L1-positive sRCC compared with the PD-L1-negative subgroup. There was no statistically significant difference in OS between PD-1-positive and negative subgroups. According to our study, the univariate and multivariate analysis indicated that pathological T3 and T4 was an independent risk factor in PD-1-positive sRCC.
We studied the relationship between PD-1/PD-L1 expression and clinicopathological characteristics in sRCC. The findings may provide valuable implications for clinical prediction.
肉瘤样肾细胞癌（sRCC）约占所有肾癌的 4%-5%。既往研究表明，sRCC 中 PD-1 和 PD-L1 的表达高于非 sRCC。本研究旨在探讨 sRCC 中 PD-1/PD-L1 的表达及其与临床病理特征的关系。
本研究纳入了 2012 年 1 月至 2022 年 1 月期间诊断为 sRCC 的 59 例患者。采用免疫组织化学染色法检测 sRCC 中 PD-1 和 PD-L1 的表达，并采用 χ2 检验和 Fisher 确切检验分析其与临床病理参数的相关性。Kaplan-Meier 曲线和对数秩检验用于描述总生存期（OS）。采用 Cox 比例风险回归分析评估临床病理参数对 OS 的预后意义。
在 59 例患者中，PD-1 和 PD-L1 的阳性表达分别为 34 例（57.6%）和 37 例（62.7%）。PD-1 表达与任何参数均无显著相关性。然而，PD-L1 表达与肿瘤大小和病理 T 分期显著相关。PD-L1 阳性 sRCC 患者的 OS 短于 PD-L1 阴性亚组。PD-1 阳性和阴性亚组的 OS 无统计学差异。根据我们的研究，单因素和多因素分析表明，病理 T3 和 T4 是 PD-1 阳性 sRCC 的独立危险因素。
我们研究了 PD-1/PD-L1 表达与 sRCC 临床病理特征的关系。这些发现可能为临床预测提供有价值的依据。
